The Royal Medical Services (RMS) Tuesday held a ceremony at the Military Oncology Center to announce the introduction of CAR T-cell therapy to treat leukemia and lymphoma patients, who are unresponsive to other treatments. CAR T-cell therapy, a living drug, are made by collecting T cells from the patient and re-engineering them in the laboratory to produce proteins on their surface called chimeric antigen receptors, or CARs. The CARs recognize and bind to specific proteins, or antigens, on the surface of cancer cells. "This achievement is the first of its kind in the Kingdom and the region that came after long preparation by the most skilled doctors and supporting medical professionals, who continued intensive work and training for a whole year to make and modify T-cells in the stem cell laboratory at the Oncology Center," said the RMS Director General. He said the RMS is keen to keep pace with developments and technologies to provide best treatment for patients according to the highest local and internati onal medical standards, and offer up-to-date medical methods for the category of blood diseases and awareness of the disease," he said. The Royal Medical Service, he added, has opened the door to cooperation with medical institutions and hospitals, whether in Jordan or the Arab world and the whole world. Source: Jordan News Agency